Adaptive Biotechnologies Corporation and Flatiron Health announced the integration of Adaptive's clonoSEQ test for measurable residual disease (MRD) assessment into OncoEMR, Flatiron's cloud-based Electronic Medical Record platform. The integration, effective July 1, 2025, provides over 4,500 clinicians across the Flatiron network of 1,000 community-based cancer care locations in the U.S. with streamlined access to MRD testing for lymphoid malignancies.
Enhanced Workflow Integration
The integration enables providers to order and review clonoSEQ MRD testing results directly within the EMR through OncoEMR's Molecular Profiling Integration (MPI) platform. This streamlined approach leads to more efficient testing workflows and increases real-time insights into patients' disease status.
"This collaboration with Flatiron demonstrates our shared commitment to empowering providers in community oncology practices, where the majority of Americans receive their cancer care," said Susan Bobulsky, Chief Commercial Officer, MRD at Adaptive Biotechnologies. "By streamlining access to vital MRD data, we enable community clinicians managing blood cancer patients to make more informed and personalized treatment decisions."
Clinical Significance of MRD Testing
MRD refers to the small number of cancer cells that may remain in a patient's body during and after treatment and may eventually lead to disease recurrence. MRD status serves as one of the strongest predictors of outcomes in blood cancer patients, with routine testing providing a personalized approach to track individual patient responses to treatment and inform clinical decision-making.
Quincy Weatherspoon, VP & GM, Flatiron Point of Care Solutions at Flatiron Health, emphasized the platform's benefits: "MPI has demonstrated benefits for providers and for labs, as it facilitates rapid and accurate exchange of orders and results while also ensuring that every step in the testing workflow is interconnected and transparent."
clonoSEQ Technology and Regulatory Status
clonoSEQ is the first and only FDA-cleared in vitro diagnostic test for detecting and tracking minimal residual disease in patients with multiple myeloma or B-cell acute lymphoblastic leukemia using bone marrow, and in patients with chronic lymphocytic leukemia using blood or bone marrow. The test is also available for diffuse large B-cell lymphoma, mantle cell lymphoma, and other lymphoid cancers as a CLIA-validated laboratory developed test.
The diagnostic platform identifies and quantifies DNA sequences in malignant cells with remarkable sensitivity, detecting one cancer cell in one million healthy cells. This precision enables clinicians and researchers to assess and monitor MRD over time, delivering standardized results that inform treatment decisions, predict outcomes, and detect relapses earlier.
clonoSEQ is covered by Medicare for multiple myeloma, chronic lymphocytic leukemia, acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and mantle cell lymphoma. The test is also CE-marked under the EU In Vitro Diagnostic Regulation.
Expanding Access Beyond Integration
While the OncoEMR integration represents a significant advancement in accessibility, clonoSEQ remains available to providers outside the Flatiron network through a rapidly expanding number of other EMR integrations and via Adaptive's online diagnostic portal, ensuring broad access to this critical diagnostic tool across the oncology community.
